UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: July 22, 2024
Commission File Number: 001-38974
BIOPHYTIS S.A.
(Translation of registrant’s name into
English)
Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment
A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨
Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On July 22, 2024, Biophytis S.A. issued a press release announcing
the deployment of its partnership strategy in Asia. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
BIOPHYTIS S.A. |
|
|
|
Date: July 22, 2024 |
By: |
/s/ Stanislas Veillet |
|
|
Name: Stanislas Veillet |
|
|
Title: Chairman and Chief Executive Officer |
Exhibit 99.1
Press release
Biophytis deploys
its partnership strategy and signs two contracts with local agents in Asia
Paris, France,
Cambridge (Massachusetts, USA), 22 July 2024 – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis”
or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases,
today announces the deployment of its partnership strategy in Asia.
To
expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South
Korea, the other for China and Southeast Asia. These agents will leverage their networks within the pharmaceutical sector to support
Biophytis in identifying partners for the drug candidate BIO101 (20-hydroxyecdysone) in these different countries.
This initiative
is part of the partnership development strategy in Asia, aimed at accelerating the deployment of BIO101 in this key geography, the
second largest pharmaceutical market in the world. Biophytis is determined to establish successful collaborations to meet patients' needs
and make significant advances in the various targeted pathologies.
Japan and China
are two strategic markets for Biophytis. Indeed, Japan has the largest population in the world suffering from sarcopenia, with more than
1 in 5 people aged 60 and over affected (source: Yuan 2023, Epidemiology of Sarcopenia, Metabolism). Additionally, more than 70 million
Chinese adults are affected by obesity, making it the second-largest population worldwide with this pathology (source: https://www.worldobesity.org/).
Following the exclusive
license agreement signed with Blanver, one of the leading pharmaceutical companies in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin
America, Biophytis aims to sign new co-development and commercialization agreements with industrial partners in Asia and also
in North America, the world's largest pharmaceutical market.
* * * *
About BIOPHYTIS
Biophytis SA is
a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone),
our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy,
phase 1-2 study to be started, respiratory (Covid-19, phase 2 completed) and metabolic diseases (obesity, phase 2 to be started). The
company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker:
ALBPS -ISIN: FR0012816825). For more information, visit www.biophytis.com
Press
release
Forward-looking
statements
This press release
contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects,"
"potential," "continues," "may," "will," "should," "could," "seeks,"
"predicts," "intends," "trends," "plans," "estimates," "anticipates" or the
negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers
to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified,
which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject
to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors
that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk
and uncertainties the Company is to face» section from the Company’s 2023 Financial Report available on BIOPHYTIS website
(www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities
and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result
of new information, future developments or otherwise, except as required by law.
Contacts Biophytis
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
Media
Antoine Denry: antoine.denry@taddeo.fr
– +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr
– +33 6 38 31 90 50
Biophytis (PK) (USOTC:BPTSY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Biophytis (PK) (USOTC:BPTSY)
Historical Stock Chart
From Dec 2023 to Dec 2024